At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Antioxidants; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 17 Aug 1998 No-Development-Reported for Cancer in Canada (Unknown route)
- 15 Aug 1996 Preclinical development for Cancer in Canada (Unknown route)